NASDAQ$ACLX
Arcellx Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Arcellx reported fourth quarter and year-end financial results, highlighted by an expanded strategic partnership with Kite and robust long-term responses from the Phase 1 expansion trial of anito-cel.
Arcellx reported collaboration revenue of $63.1 million for the fourth quarter of 2023 and ended the quarter with $729.2 million in cash, cash equivalents, and marketable securities, extending the cash runway into 2027. Net income for the quarter was $20.5 million.
- Expanded strategic partnership with Kite Pharma, Inc. to include co-development of anito-cel for lymphomas and Kite exercising its option to license ACLX-001.
- Presented continued robust long-term responses from lead product candidate anito-cel evaluated in a Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma, at 65th ASH Annual Meeting and Exposition.
- Ended the quarter with $729.2 million in cash, extending cash runway into 2027.
- Collaboration revenue was $63.1 million for the quarter.
Headline financials
Revenue & EPS history
Arcellx · Revenue · Quarterly
$63.1M
Forward guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
+2.2%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+24.9%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+16.0%
Q2 2024
Best reaction
-4.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.2% | -0.1% | +0.2% | |
| Q3 2025 | -1.9% | +2.2% | -21.1% | |
| Q2 2025 | -0.9% | -0.2% | +2.1% | |
| Q1 2025 | -0.2% | +10.9% | +9.0% | |
| Q4 2024 | +2.0% | +1.2% | -19.9% | |
| Q3 2024 | +10.8% | +8.1% | -9.1% | |
| Q2 2024 | +16.0% | +19.1% | +40.0% | |
| Q1 2024 | -4.8% | -3.1% | -2.8% | |
| Q4 2023 | -2.7% | +0.4% | +2.9% | |
| Q3 2023 | +4.3% | +21.3% | +11.0% | |
| Q2 2023 | +6.7% | +3.3% | -0.7% | |
| Q1 2023 | +2.8% | -4.5% | -3.7% | |
| Q4 2022 | +0.9% | -2.9% | +41.1% | |
| Q3 2022 | -2.8% | -4.9% | +47.5% | |
| Q3 2021 | -2.8% | -4.9% | +47.5% | |
| Q2 2022 | +8.4% | -4.1% | +10.5% | |
| Q1 2022 | +0.2% | -15.5% | +174.8% | |
| Q1 2021 | +0.2% | -15.5% | +174.8% | |
| Q4 2021 | +5.9% | -8.7% | -30.2% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro